Just-Evotec Biologics与Sandoz扩大生物仿制药技术合作伙伴关系-动脉网

Just - Evotec Biologics Expands Tech Partnership for Biosimilars with Sandoz

BioSpace 等信源发布 2024-07-08 20:48



可切换为仅中文







Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars

Just-Evotec Biologics与Sandoz扩大合作伙伴关系，开发和商业制造生物仿制药

Additional biosimilars potentially to be added to Sandoz development pipeline

Sandoz开发管道中可能添加的其他生物仿制药

Further guarantees for Sandoz long-term commercial supply security

桑多斯长期商业供应安全的进一步保障

HAMBURG, GERMANY and SEATTLE, WA / ACCESSWIRE / July 8, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced that its biologics segment, Just - Evotec Biologics, Inc., has expanded its strategic partnership with Sandoz. Just - Evotec Biologics will receive appropriate remuneration following early scientific validation, with further funding tied to achieving development milestones from 2025..

德国汉堡和华盛顿州西雅图/ACCESSWIRE/2024年7月8日/Evotec SE（法兰克福证券交易所：EVT）（纳斯达克：EVO）（MDAX/TecDAX，ISIN：DE0005664809）今天宣布，其生物制品部门Just-Evotec biologics，Inc.扩大了与Sandoz的战略合作伙伴关系。Just-Evotec Biologics将在早期科学验证后获得适当的报酬，进一步的资金将与2025年实现发展里程碑挂钩。。

This expanded partnership solidifies Just - Evotec Biologics' commitment to providing long-term commercial supply of biosimilars to Sandoz from its newly built J.POD® biologics manufacturing facility at Evotec's Campus Curie in Toulouse, France. Sandoz secures further guarantees relating to long-term supply for patients with a reservation of significant commercial manufacturing capacity..

这一扩大的合作关系巩固了Just-Evotec Biologics的承诺，即从其位于法国图卢兹的Evotec居里校区新建的J.POD®生物制品制造厂向Sandoz提供长期商业供应的生物仿制药。Sandoz保证为保留重要商业制造能力的患者提供长期供应的进一步保障。。

Since May 2023, Just - Evotec Biologics and Sandoz have been engaged in a multi-year technology partnership aimed at the rapid development and manufacturing of biosimilars. Leveraging its data-driven, fully integrated design capability and continuous manufacturing technology platform (J.DESIGN), Just - Evotec Biologics aims to deliver the highest product quality and cost efficiency to its partners.

自2023年5月以来，Just-Evotec Biologics和Sandoz一直在进行多年的技术合作，旨在快速开发和制造生物仿制药。Just-Evotec Biologics利用其数据驱动、完全集成的设计能力和连续制造技术平台（J.design），旨在为其合作伙伴提供最高的产品质量和成本效益。

This collaboration aligns with Evotec's mission to improve access to medicines for patients across the globe..

这项合作符合Evotec的使命，即改善全球患者获得药物的机会。。

Dr Matthias Evers, Chief Business Officer of Evotec, commented: 'We are thrilled to expand our partnership with Sandoz, building on the successes we've achieved since the initial launch. Introducing additional molecules has the potential to enhance access for millions of patients, while commercial manufacturing from Toulouse will ensure the long-term supply of Sandoz' biosimilar portfolio.

Evotec首席商务官马蒂亚斯·埃弗斯（MatthiasEvers）博士评论道：“我们很高兴能够在首次推出以来取得的成功基础上，扩大与桑德斯的合作伙伴关系。引入额外的分子有可能增加数百万患者的使用机会，而图卢兹的商业制造将确保Sandoz生物仿制药组合的长期供应。

This commercial supply aspect also validates our strategy to establish our second J.POD® in Toulouse.'.

这一商业供应方面也验证了我们在图卢兹建立第二个J.POD®的战略。

About Sandoz

关于Sandoz

Sandoz (SDZ; SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. 20,000 people of more than 100 nationalities work together to ensure 800 million patient treatments are provided annually by Sandoz, generating substantial global healthcare savings and an even larger total social impact.

Sandoz（SDZ；SDZNY）是仿制药和生物仿制药的全球领导者，其发展战略由其宗旨驱动：开创患者的获取途径。来自100多个国家的20000多人共同努力，确保Sandoz每年为8亿患者提供治疗，从而为全球医疗保健节省了大量资金，并产生了更大的总体社会影响。

Its leading portfolio of 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to the year 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world's first oral penicillin in 1951, and the first biosimilar in 2006.

其领先的1500种产品组合解决了从普通感冒到癌症的各种疾病。Sandoz总部位于瑞士巴塞尔，其历史可以追溯到1886年。它的突破历史包括1929年的Sandoz钙，1951年世界上第一种口服青霉素，2006年第一种生物仿制药。

In 2023, Sandoz achieved sales of USD 9.6 billion..

2023年，桑多斯销售额达到96亿美元。。

About Just - Evotec Biologics

关于Just-Evotec Biologics

Just - Evotec Biologics, wholly owned by Evotec SE, is a first-to-industry biologics platform company that leverages AI/ML technologies and world-leading molecular design, cell line development, process intensification and continuous manufacturing strategies to advance biotherapeutics from discovery through clinical stages to commercial launch.

Just-Evotec Biologics是Evotec SE全资拥有的第一家行业生物制剂平台公司，它利用AI/ML技术和世界领先的分子设计，细胞系开发，过程强化和连续制造策略，将生物治疗药物从发现到临床阶段推进到商业推出。

The Just - Evotec Biologics team combines deep industry experience in the fields of data, protein, process, and manufacturing sciences including automation with highly integrated and flexible capabilities to break through the scientific and economic barriers associated with the development of protein therapeutics.

Just-Evotec Biologics团队将数据、蛋白质、工艺和制造科学领域的丰富行业经验（包括自动化）与高度集成和灵活的能力相结合，以突破与蛋白质疗法开发相关的科学和经济障碍。

Our focus is to accelerate and expand access to biotherapeutics through scientific and technological innovation for our proprietary projects and on behalf of our partners. Learn more at www.just-evotecbiologics.com..

我们的重点是通过我们专有项目的科技创新，并代表我们的合作伙伴，加速和扩大获得生物治疗药物的机会。。。

About Evotec SE

关于Evotec SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products.

Evotec是一家生命科学公司，拥有独特的商业模式，致力于发现和开发高效的治疗方法，并将其提供给患者。该公司的多模式平台包括创新技术、数据和科学的独特组合，用于发现、开发和生产一流和一流的药品。

Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g.

Evotec为所有前20大制药公司和800多家生物技术公司、学术机构以及其他医疗保健利益相关者提供高价值的合作伙伴关系和解决方案。Evotec在目前服务不足的广泛治疗领域开展了战略活动，包括。

neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development.

神经病学、肿瘤学以及代谢和传染病。在这些专业领域内，Evotec旨在创建世界领先的创新疗法共同拥有的管道，迄今为止，已建立了200多个专有和共同拥有的研发项目组合，从早期发现到临床开发。

Evotec operates globally with more than 5,000 highly qualified people. The Company's sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on X/Twitter @Evotec and LinkedIn..

。该公司在欧洲和美国的网站提供高度协同的技术和服务，并作为互补的卓越集群运营。有关更多信息，请访问www.evotec.com，并在X/Twitter@evotec和LinkedIn上关注我们。。

Forward-looking statements

前瞻性声明

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements.

本公告包含有关未来事件的前瞻性声明，包括Evotec证券的拟议发售和上市。诸如“预期”、“相信”、“可能”、“估计”、“期望”、“打算”、“可能”、“可能”、“计划”、“潜力”、“应该”、“目标”、“将会”等词语以及这些词语和类似表达的变体旨在识别前瞻性陈述。

Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made.

这些声明包括对Evotec收入预期、集团息税折旧摊销前利润和未经授权的研发费用的评论。这些前瞻性陈述基于Evotec在做出这些陈述时认为合理的可用信息以及期望和假设。

No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec.

无法保证这些期望将被证明是正确的。这些声明涉及已知和未知的风险，并基于一些假设和估计，这些假设和估计固有地受到重大不确定性和意外事件的影响，其中许多不受Evotec的控制。

Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based..

Evotec明确否认有义务或承诺公开发布本文所含任何前瞻性声明的任何更新或修订，以反映Evotec对此预期的任何变化，或任何声明所依据的事件、条件或情况的任何变化。。

For further information, please contact:

欲了解更多信息，请联系：

Media

媒体

Gabriele Hansen

加布里埃尔·汉森

SVP Head of Global Corporate Communications

全球企业传播高级副总裁

Gabriele.Hansen@evotec.com

Hinnerk Rohwedder

Director of Global Corporate Communications